Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 4,90 M
EBIT 2017 -30,0 M
Net income 2017 -30,0 M
Finance 2017 11,0 M
Yield 2017 -
Sales 2018 21,0 M
EBIT 2018 -3,00 M
Net income 2018 -3,00 M
Finance 2018 7,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 39,2x
EV / Sales2018 9,35x
Capitalization 203 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : - Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
07/05 Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiD..
05/23 Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive..
05/10 Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carc..
04/26 ONXEO : Annual General Meeting of April 26, 2017
04/26 ONXEO : Q1 2017 Financial Information and Business Update
04/25 ONXEO : Publication of 2016 Registration Document
04/25 ONXEO : Announces Publication of 2016 Reference Document
04/24 Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe..
04/24 Onxeo Announces Publication of 2016 Reference Document
04/24 ONXEO : Clinigen and Onxeo initiate Managed Access programme for belinostat in E..
More news
Sector news : Pharmaceuticals - NEC
01:15pDJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08:35aDJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
08/17 Exclusive - Taking aim at China, India tightens power grid, telecoms rules
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,40 €
Spread / Average Target 84%
EPS Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Françoise Bono Chief Scientific Officer
Olivier de Beaumont Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA239
JOHNSON & JOHNSON15.48%357 079
ROCHE HOLDING LTD.5.37%218 752
NOVARTIS10.59%218 545
PFIZER1.45%196 221
MERCK AND COMPANY5.05%168 660